Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted...
Shining at CES 2025, TCL Garners Multiple Awards for Display Innovations and Smart Home Solutions
LAS VEGAS, Jan. 15, 2025 /PRNewswire/ -- TCL Electronics, a leading consumer electronics brand and the world's top two TV brand, has been honored with multiple awards at CES 2025, demonstrating its technological excellence in display innovations and...
ATFX Connect Won Best B2B Liquidity Provider (Prime of Prime) at Finance Magnates London Summit 2024
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- ATFX Connect, the institutional arm of global trading platform ATFX, has been named Best B2B Liquidity Provider (Prime of Prime) at the 2024 Finance Magnates London Summit (FMLS). The award acknowledges the...
Infineon wins German Sustainability Award 2025
– Infineon wins prestigious award in the category "Electrical Engineering and Electronics". – The company makes significant progress in implementing its ambitious sustainability strategy. – German Sustainability Award is Europe's largest award for...
Ping An Wins Sixth Director of the Year Award and Inaugural Climate Governance Award from the Hong Kong Institute of Directors
HONG KONG and SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318/82318, SSE: 601318) received the Director of the Year Award and the Climate Governance Award for...
ZICC: Closer China- Honduras Ties
BEIJING, Nov. 23, 2024 /PRNewswire/ -- Renato Florentino, vice president of Honduras, accepted an exclusive interview with ZICC in Wuzhen during the 2024 World Internet Conference Wuzhen Summit. He said that China's advancements in transportation,...
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
HONG KONG, Nov. 22, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sNDA) for penpulimab, a...